We report that individuals with type 1 diabetes treated with SGLT2i therapy demonstrate preservation of renal function, reduced rates of hospitalisation and reduced risk of heart failure when compared with patients receiving GLP-1 RA. Here, GLP1R is linked to type 1 diabetes mellitus.